S&P 500
(-0.12%) 5 414.60 points
Dow Jones
(-0.52%) 38 510 points
Nasdaq
(0.00%) 17 609 points
Oil
(0.10%) $78.58
Gas
(-2.50%) $2.97
Gold
(-1.74%) $2 313.80
Silver
(-4.55%) $28.89
Platinum
(-1.71%) $954.40
USD/EUR
(0.75%) $0.932
USD/NOK
(0.95%) $10.67
USD/GBP
(0.43%) $0.785
USD/RUB
(-0.69%) $88.38

Realtime updates for Innate Pharma SA [IPH.PA]

Exchange: EURONEXT Industry: Biotechnology
Last Updated13 Jun 2024 @ 11:35

-2.43% 2.21

Live Chart Being Loaded With Signals

Commentary (13 Jun 2024 @ 11:35):

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally...

Stats
Today's Volume 54 998
Average Volume 72 283
Market Cap 178.26M
EPS €-0.110 ( Q4 | 2023-12-31 )
Next earnings date ( €0 ) 2024-09-12
Last Dividend €0 ( N/A )
Next Dividend €0 ( N/A )
P/E -24.50
(Sector) 0
(Industry) 0
ATR14 €0.00800 (0.36%)
ABNX.PA -1.57%
ABVX.PA -1.68%
ACPH.BR 0.00%
ADOC.PA -8.74%
ADVIC.PA 0.00%
ALBPS.PA -0.76%
ALCLS.PA -3.22%
ALGEN.PA -5.45%
ALHYG.PA -15.83%
ALMDP.PA -2.50%
ALNEV.PA -14.70%
ALNFL.PA -7.72%
ALNOX.PA 0.00%
ALPHA.PA 4.55%
ALPHE.PA -0.50%
ALQGC.PA -4.07%
ALSEN.PA -6.76%
ALTHX.PA 0.00%
ALVAL.PA -17.91%
ALVET.PA -1.05%
APM.PA 0.00%
ARGX.BR 2.37%
ASIT.BR 0.00%
ATRY.MC -1.07%
BIO3.DE 0.00%
BIOM3.SA -2.81%
COX.PA 0.00%
CYAD.BR 3.16%
DBV.PA 0.10%
ERYP.PA 0.25%
FALG.PA -8.05%
GKTX.PA 0.00%
GNFT.PA -5.26%
IPH.PA -2.43%
IVA.PA 2.95%
MAAT.PA -1.29%
MEDCL.PA -0.27%
NANO.PA -2.60%
OSE.PA -7.20%
OXUR.BR 0.00%
PHM.MC -5.27%
POXEL.PA -0.17%
ROVI.MC -0.96%
SIGHT.PA -4.03%
TNG.PA -3.59%
TUB.BR -0.37%
UCB.BR 0.52%
VLA.PA -8.87%

Volume Correlation

Long: 0.06 (neutral)
Short: 0.32 (neutral)
Signal:(49.008) Neutral

Innate Pharma SA Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Innate Pharma SA Correlation - Currency/Commodity

The country flag -0.70
( moderate negative )
The country flag -0.78
( moderate negative )
The country flag 0.00
( neutral )
The country flag -0.89
( strong negative )
The country flag 0.00
( neutral )
The country flag 0.35
( neutral )

Innate Pharma SA Financials

Annual 2023
Revenue: €51.90M
Gross Profit: €-4.12M (-7.94 %)
EPS: €-0.0941
FY 2023
Revenue: €51.90M
Gross Profit: €-4.12M (-7.94 %)
EPS: €-0.0941
FY 2022
Revenue: €49.64M
Gross Profit: €-2.02M (-4.08 %)
EPS: €-1.240
FY 2021
Revenue: €12.11M
Gross Profit: €0.00 (0.00 %)
EPS: €-0.669

Financial Reports:

No articles found.

Innate Pharma SA Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Innate Pharma SA

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Total Execution Time: 1.904452085495 seconds
Number of API calls: 3
Number of DB calls: 9